Study guide

3.2 Pathology Interpretation, Histology & Tumor Grading

Advanced Oncology Certified Nurse Practitioner AOCNP

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction & Exam Overview

1.1 About the AOCNP Exam 1.2 How to Use This AOCNP Study Guide

2 Chapter 2: Cancer Continuum - Risk, Prevention & Screening

2.1 Cancer Risk Factors, At-Risk Populations & Health Disparities 2.2 Primary Prevention, Vaccination, Chemoprevention & Risk-Reducing Surgery 2.3 Cancer Screening & Early Detection Guidelines 2.4 Screening for Subsequent & Second Primary Malignancies 2.5 Hereditary Cancer Syndromes & Genetic Counseling

3 Chapter 3: Cancer Continuum - Assessment, Diagnosis & Staging

3.1 Diagnostic Workup, Tissue Biopsy & Biomarker Evaluation 3.2 Pathology Interpretation, Histology & Tumor Grading 3.3 Cancer Staging Systems (TNM) & Prognostication Models 3.4 Performance Status, Frailty & Geriatric Assessment

4 Chapter 4: Cancer Continuum - Planning, Coordination & Survivorship

4.1 Established Guidelines for Care & Categories of Evidence 4.2 Individualized Treatment Planning & Molecular Tumor Boards 4.3 Reproductive Planning & Fertility Preservation 4.4 Patient Navigation & Interprofessional Care Coordination 4.5 Survivorship Care Planning & Late Effects Management 4.6 Post-Treatment Surveillance for Cancer Recurrence

5 Chapter 5: Cancer Treatment - Antineoplastic Pharmacology & Chemotherapy

5.1 Antineoplastic Principles, Dosing & Dose Adjustments 5.2 Cytotoxic Chemotherapy Classes & Adverse Effect Management 5.3 Safe Administration, Handling & Infusion Toxicities 5.4 Oral Antineoplastic Therapy: Adherence, Interactions & Monitoring

6 Chapter 6: Cancer Treatment - Targeted, Immuno & Hormonal Therapies

6.1 Targeted Therapies, Tyrosine Kinase Inhibitors & ADCs 6.2 Cancer Immunotherapy, Checkpoint Inhibitors & CAR T-Cell Therapy 6.3 Endocrine & Hormonal Therapies in Oncology

7 Chapter 7: Cancer Treatment - Radiation, Surgery, Regional & Multimodal Therapy

7.1 Radiation Oncology Principles & Toxicity Management 7.2 Surgical Oncology, Perioperative Care & Reconstruction 7.3 Regional & Localized Therapy Administration 7.4 Multimodal Therapy & Treatment Sequencing 7.5 Complementary, Alternative & Integrative Therapies

8 Chapter 8: Cancer Treatment - Transplantation, Clinical Trials & Response

8.1 Hematopoietic Stem Cell Transplantation (HSCT) & Cell Therapy 8.2 Clinical Trials, Research Protocols & Response Evaluation (RECIST)

9 Chapter 9: Supportive Care - Pain & Controlled Substance Safety

9.1 Cancer Pain Assessment & Comprehensive Analgesic Management 9.2 Controlled Substance Safety & Opioid Stewardship 9.3 Nonpharmacologic & Integrative Symptom Interventions

10 Chapter 10: Supportive Care - Symptom & Comorbidity Management

10.1 Acute, Late & Long-Term Patterns of Treatment-Related Symptoms 10.2 Gastrointestinal Symptom Management (CINV, Mucositis, Diarrhea) 10.3 Hematologic & Neurologic Toxicity Management 10.4 Dermatologic, Metabolic & Fatigue Management 10.5 Cancer-Associated Thrombosis & Anticoagulation 10.6 Comorbid Conditions & Their Interaction With Cancer Treatment 10.7 Palliative Care, Hospice & End-of-Life Management

11 Chapter 11: Oncologic Emergencies

11.1 Superior Vena Cava Syndrome & Structural Emergencies 11.2 Spinal Cord Compression & Neurologic Emergencies 11.3 Metabolic Emergencies: Tumor Lysis Syndrome & Hypercalcemia of Malignancy 11.4 Febrile Neutropenia, Sepsis & Vesicant Extravasation 11.5 Cardiopulmonary & Airway Emergencies 11.6 Hematologic & Endocrine Emergencies: DIC, Leukostasis, Hyperviscosity & SIADH

12 Chapter 12: Psychosocial Issues

12.1 Psychosocial Assessment & Distress Screening in Oncology 12.2 Risk Factors & At-Risk Oncology Populations 12.3 Psychosocial & Emotional Sequelae of Disease and Treatment 12.4 Psychiatric & Psychosocial Comorbidities in Cancer Care 12.5 Caregiver Burden, Support & Community Resources

13 Chapter 13: Professional Practice & Roles of the APRN

13.1 APRN Scope of Practice, Prescriptive Authority & Standards of Care 13.2 Bioethics, Informed Consent & Quality Improvement in Oncology 13.3 Cultural Competence, Implicit Bias & Equitable Oncology Care 13.4 Accreditation Standards & Outcomes of APRN Practice 13.5 Competency Evaluation, Peer Review & Peer Education

3.2 Pathology Interpretation, Histology & Tumor Grading

Key Takeaways Explain This Topic AI

Tumor grade describes the microscopic degree of cellular differentiation and architectural atypia (GX to G4), serving as a direct reflection of intrinsic tumor biological aggressiveness.

Cellular differentiation reflects how closely neoplastic cells resemble normal tissue counterpart; well-differentiated tumors (Grade 1) behave less aggressively than poorly differentiated (Grade 3) or undifferentiated/anaplastic (Grade 4) tumors.

Immunohistochemistry (IHC) utilizes specific antibody-antigen staining panels (e.g., Cytokeratins [CK7/CK20], TTF-1, CD45, S100, Synaptophysin/Chromogranin) to determine tissue of origin in carcinoma of unknown primary (CUP) and subtyping poorly differentiated tumors.

Histologic classification categorizes solid tumors by cellular origin: Carcinomas (epithelial origin), Sarcomas (mesenchymal/connective tissue origin), Lymphomas/Leukemias (hematopoietic origin), and Melanomas (melanocytic origin).

Surgical resection margin status dictates local recurrence risk: R0 indicates microscopic negative margins, R1 indicates microscopic positive margins at the inked edge, and R2 indicates macroscopic gross residual tumor remaining.

Last updated: August 2026

1.4 Pathology Interpretation, Histology & Tumor Grading

Clinical Blueprint Focus: Deciphering surgical pathology reports is a core competency for advanced practice oncology nurses. The AOCNP exam tests histologic cell lineage classification (carcinoma vs. sarcoma vs. lymphoma), cellular grading systems (Gleason, SBR/Nottingham, FNCLCC), immunohistochemical (IHC) lineage profiles, proliferation markers (Ki-67), and surgical margin status definitions (R0, R1, R2).

Histologic Classification & Cell Lineage of Origin

Malignancies are classified based on the embryonic tissue layer and cellular origin from which they arise:

Carcinomas (Epithelial Cell Origin): Comprise >80% of adult solid tumors, originating from ectodermal or endodermal epithelial tissue. Subdivided into:

Adenocarcinomas: Arise from glandular epithelium (e.g., colon, breast, prostate, lung, pancreas).

Squamous Cell Carcinomas: Arise from protective non-glandular stratified squamous epithelium (e.g., head and neck, esophagus, cervix, lung).

Urothelial (Transitional Cell) Carcinomas: Arise from the bladder and renal pelvis lining.

Sarcomas (Mesenchymal / Connective Tissue Origin): Arise from mesodermal tissues (bone, cartilage, fat, muscle, blood vessels). Subdivided into osteosarcomas, chondrosarcomas, leiomyosarcomas (smooth muscle), liposarcomas (adipose), and angiosarcomas.

Hematologic Malignancies (Hematopoietic Origin): Arise from immune and blood-forming elements. Includes Lymphomas (Hodgkin vs. Non-Hodgkin), Leukemias (AML, ALL, CML, CLL), and Multiple Myeloma (plasma cells).

Melanomas: Arise from neuroectodermal melanocytes.

Histological Tumor Grading Systems

Tumor grade describes the microscopic degree of cellular differentiation, nuclear pleomorphism, and mitotic activity. Unlike stage (which describes anatomical extent), grade reflects intrinsic biological aggressiveness.

General AJCC Grading Scale

GX: Grade cannot be assessed.

G1 (Well-Differentiated / Low Grade): Cells closely resemble normal host cells; uniform nuclei; low mitotic rate.

G2 (Moderately Differentiated / Intermediate Grade): Intermediate structural atypia and mitotic figures.

G3 (Poorly Differentiated / High Grade): Marked cellular pleomorphism, loss of tissue architecture, high mitotic counts.

G4 (Undifferentiated / Anaplastic / High Grade): Complete loss of cellular differentiation features; highly aggressive.

Specialty-Specific Grading Systems

Prostate Cancer (Gleason Score / ISUP Grade Group): Evaluates primary and secondary architectural patterns (scale 1 to 5). Total Gleason score = Primary Pattern + Secondary Pattern (e.g., 3 + 4 = 7). Re-categorized into ISUP Grade Groups 1 (Gleason ≤6) to 5 (Gleason 9–10).

Breast Cancer (Nottingham / Scarff-Bloom-Richardson System): Evaluates three features (scored 1–3 each): Tubule formation, Nuclear pleomorphism, and Mitotic count. Total score 3–5 = Grade 1; 6–7 = Grade 2; 8–9 = Grade 3.

Soft Tissue Sarcoma (FNCLCC System): Evaluates Tumor differentiation, Mitotic count, and Tumor necrosis percentage.

Neuroendocrine Tumors (WHO NET Grading): Graded strictly by Ki-67 proliferation index and mitotic count per 10 high-power fields (HPF) :

Grade 1: Ki-67 < 3% AND < 2 mitoses/10 HPF.

Grade 2: Ki-67 3% to 20% OR 2 to 20 mitoses/10 HPF.

Grade 3: Ki-67 > 20% OR > 20 mitoses/10 HPF.

Diagnostic Immunohistochemistry (IHC) Panels

Immunohistochemistry uses labeled monoclonal antibodies to identify specific cell-surface and intracellular protein antigens, establishing cell lineage in poorly differentiated tumors or carcinomas of unknown primary (CUP).

  • IHC Marker Panel Staining Pattern / Positive Lineage Clinical Application
  • CD45 (Leukocyte Common Antigen - LCA) Hematopoietic / Lymphoid cells Differentiates Lymphoma from Carcinoma
  • Pan-Cytokeratin (AE1/AE3, OSCA) Epithelial cells (Carcinomas) Confirms Carcinoma lineage
  • S100 / SOX10 / HMB-45 / Melan-A Melanocytic cells Diagnoses Melanoma
  • Vimentin Mesenchymal cells Suggests Sarcoma lineage
  • Cytokeratin 7 (CK7) & CK20 Profile Organ-specific epithelial subtyping Diagnoses Carcinoma of Unknown Primary
  • TTF-1 (Thyroid Transcription Factor-1) Nuclear staining in Lung & Thyroid Confirms primary Lung Adenocarcinoma
  • CDX2 / SATB2 Nuclear staining in Gastrointestinal epithelium Confirms primary Colorectal Adenocarcinoma
  • Synaptophysin & Chromogranin A Neuroendocrine cell cytoplasm Diagnoses Neuroendocrine Tumors (NETs)
  • GATA3 / ER / PR Luminal breast epithelial cells Confirms primary Breast Adenocarcinoma
  • CK7 / CK20 Diagnostic Matrix for Unknown Primary

CK7+ / CK20-: Lung, Breast, Thyroid, Ovary, Endometrium.

CK7- / CK20+: Colorectal, Merkel cell carcinoma.

CK7+ / CK20+: Urothelial (bladder), Pancreatic, Gastric.

CK7- / CK20-: Renal cell, Prostate, Hepatocellular carcinoma.

Surgical Resection Margin Status

Pathologic reporting of surgical margins describes the microscopic relationship between neoplastic cells and the inked outer edge of the resected specimen: Resection Margin Code Microscopic & Macroscopic Findings Clinical Impact

  • -------------------- ---------------------------------- ---------------
  • R0 Resection No tumor cells at the inked margin Negative margins; optimal local

(Microscopically negative). control achieved.

  • R1 Resection Microscopic tumor cells present at Microscopic positive margins;
  • the inked surgical margin. warrants re-excision or adjuvant

radiation therapy.

R2 Resection Macroscopic (gross) tumor visible Gross residual disease left;

and remaining in surgical bed. high local recurrence rate.

Clinical Pearl: Lymphovascular invasion (LVI) and perineural invasion (PNI) documented on a pathology report represent key micro-pathologic risk features. The presence of LVI or PNI indicates higher risk of regional lymph node metastasis and systemic recurrence, often altering adjuvant chemotherapy decisions even in early-stage disease.

Loading diagram... Immunohistochemistry Lineage Diagnostic Algorithm